Advanced search
Publication Cover
Clinical and Experimental Hypertension Volume 32, 2010 - Issue 2
Submit an article Journal homepage
94
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Clinical and Pharmacotherapeutic Relevance of the Double-Chain Domain of the Angiotensin II Type 1 Receptor Blocker Olmesartan

Yoshihiro Kiya Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
,
Shin-Ichiro Miura Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OhioCorrespondence[email protected]
,
Masahiro Fujino Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
,
Satoshi Imaizumi Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
,
Sadashiva S. Karnik Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio
&
Keijiro Saku Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
Pages 129-136 | Received 23 Oct 2008, Accepted 19 Dec 2008, Published online: 08 Apr 2010

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Hiroyuki Daikuhara, Kensaku Fukunaga & Tomie Ohshima. (2014) Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study. Drug Design, Development and Therapy 8, pages 219-226.
Read now
Shin-ichiro Miura & Keijiro Saku. (2014) Recent progress in the treatment of cardiovascular disease using olmesartan. Clinical and Experimental Hypertension 36:7, pages 441-446.
Read now
Joji Morii, Shin-ichiro Miura, Yuhei Shiga, Makoto Sugihara, Tadaaki Arimura, Hideto Sako, Bo Zhang, Yoshinari Uehara & Keijiro Saku. (2012) Comparison of the Efficacy and Safety of Irbesartan and Olmesartan in Patients With Hypertension (EARTH Study). Clinical and Experimental Hypertension 34:5, pages 342-349.
Read now

Articles from other publishers (13)

I. А. Lukonin, V. V. Skibitsky, A. V. Fendrikova, A. V. Skibitsky & I. A. Antipov. (2023) Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease. South Russian Journal of Therapeutic Practice 4:1, pages 68-74.
Crossref
Jia Yu, Wei Fang, Xing Guo, Haiyang Jiang, Peng Sun, Yufeng Liu & Xin Jin. (2021) The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis. Computational and Mathematical Methods in Medicine 2021, pages 1-8.
Crossref
Iman Razeghian-Jahromi, Mohammad Javad Zibaeenezhad, Zhibing Lu, Elyaspour Zahra, Razmkhah Mahboobeh & Vicenzo Lionetti. (2020) Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure. Heart Failure Reviews 26:2, pages 371-380.
Crossref
Massimo Volpe, Giovanna Gallo & Giuliano Tocci. (2019) Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension: Room for monotherapy?. International Journal of Cardiology 291, pages 105-111.
Crossref
Matthias Hoffmann, Xinyu Chen, Mitsuru Hirano, Kenji Arimitsu, Hiroyuki Kimura, Takahiro Higuchi & Michael Decker. (2018) 18 F‐Labeled Derivatives of Irbesartan for Angiotensin II Receptor PET Imaging . ChemMedChem 13:23, pages 2546-2557.
Crossref
Martin C. Michel, Hans R. Brunner, Carolyn Foster & Yong Huo. (2016) Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. Pharmacology & Therapeutics 164, pages 1-81.
Crossref
Sadashiva S. Karnik, Hamiyet Unal, Jacqueline R. Kemp, Kalyan C. Tirupula, Satoru Eguchi, Patrick M. L. Vanderheyden & Walter G. Thomas. (2015) International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli. Pharmacological Reviews 67:4, pages 754-819.
Crossref
Yoshiteru Tada, Kenji Yagi, Masaaki Uno, Nobuhisa Matsushita, Yasuhisa Kanematsu, Kazuyuki Kuwayama, Kenji Shimada, Kyoko Nishi, Motohiro Hirasawa, Junichiro Satomi, Keiko T. Kitazato, Teruyoshi Kageji, Eiji Matsuura & Shinji Nagahiro. (2015) Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan. Journal of Stroke and Cerebrovascular Diseases 24:7, pages 1487-1492.
Crossref
Nayumi Shigihara, Toyoyoshi Uchida, Takashi Yorifuji, Yukiko Toyofuku, Motoyuki Tamaki, Yoshio Fujitani & Hirotaka Watada. (2013) Olmesartan and telmisartan comparably preserve pancreatic beta-cell mass with reduction of oxidative stress in db/db mice. Diabetology International 5:1, pages 62-68.
Crossref
Martin C. Michel, Carolyn Foster, Hans R. Brunner & Lisheng Liu. (2013) A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists. Pharmacological Reviews 65:2, pages 809-848.
Crossref
Shin-ichiro Miura & Keijiro Saku. (2012) How important is it to control nocturnal hypertension with angiotensin II type 1 receptor blockers?. Hypertension Research 36:3, pages 194-195.
Crossref
Mai Yanagi, Kouichi Tamura, Tetsuya Fujikawa, Hiromichi Wakui, Tomohiko Kanaoka, Masato Ohsawa, Kengo Azushima, Akinobu Maeda, Hiroyuki Kobori & Satoshi Umemura. (2012) The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertension Research 36:3, pages 262-269.
Crossref
. (2011) Current World Literature. Current Opinion in Nephrology & Hypertension 20:5, pages 561-571.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.